Condition: Ovarian Neoplasm Epithelial · Fallopian Tube Neoplasms · Ovarian Endometrioid Carcinoma · Sponsor: Swiss GO Trial Group
The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.
This description comes directly from the study's public registry record.
Maren S Vogel, PhD · +41 61 3284203 · maren.vogel@usb.ch
Team Swiss GO Trial Group · +41 61 3284203 · pm-team@swiss-go.ch
Always discuss trial participation with your own doctor first.
| Kantonsspital Baden AG | Baden, Canton of Aargau, Switzerland | Recruiting |
| Universitätsspital Basel | Basel, Canton of Basel-City, Switzerland | Recruiting |
| HOCH Health Ostschweiz Kantonsspital St.Gallen | Sankt Gallen, Canton of St. Gallen, Switzerland | Recruiting |
| Thurgau AG Frauenfeld / Münsterlingen | Frauenfeld, Thurgau, Switzerland | Recruiting |
| Inselspital Bern (University Hospital for Medical Oncology) | Bern, Switzerland | Recruiting |
| HFR-Fribourg- Hopital Cantonal | Fribourg, Switzerland | Recruiting |
| University Hospital Zurich | Zurich, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06466382